For some cancer types, such as Non‐Small Cell Lung Cancer (NSCLC), several targeted drugs acting on different mutant proteins are approved by the FDA/EMA (TKIs acting on sensitive mutant EGFR proteins or ALK inhibitors directed against the products of ALK (MIM: 105590) translocations) and exploring additional therapeutic options with medicines approved for different indications is recommended by the NCCN guidelines (crizotinib or cabozantinib/vandetanib for NSCLC with ROS1 (MIM: 165020) or RET (MIM:164761) translocations, respectively). This evidence concerns the gene ALK and cancer.